technetium tc 99m tilmanocept

**Technetium tc 99m tilmanocept** is a technetium-99m-labeled, CD206-targeted radiopharmaceutical diagnostic agent used for lymphatic mapping and sentinel lymph-node localization. The agent consists of tilmanocept, a mannose-bearing dextran-based macromolecule with DTPA chelators for technetium-99m labeling; it binds mannose receptor C-type 1 on macrophages and dendritic cells within lymphatic tissue, enabling gamma-counter and optional scintigraphic detection of tumor-draining lymph nodes. Marketed as **Lymphoseek**, it is FDA-approved for intraoperative lymphatic mapping in eligible patients with solid tumors, including clinically node-negative oral-cavity squamous cell carcinoma, breast cancer, and melanoma. Navidea Biopharmaceuticals developed the product; Cardinal Health is the current U.S. label packager and commercial rights holder. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72f31b09-4d7b-475c-b37a-9daf2ad80240))

Brand names

Lymphoseek

Other names

99mTc-tilmanoceptTc-99m tilmanoceptTc99m tilmanoceptTc 99m tilmanocepttechnetium-99m tilmanocepttechnetium99m tilmanocepttechnetium 99m tilmanocept